Three Rivers Pharmaceuticals, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals International (VRX) for $91

Three Rivers Pharmaceuticals, LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals International (VRX) for $91M

1/15/2008

CRANBERRY TOWNSHIP, Pa., Jan. 14 -- Three Rivers Pharmaceuticals, LLC finalized acquisition of the hepatitis C drug Infergen from Valeant Pharmaceuticals International . Valeant is receiving $91 million from Three Rivers for the procurement.

"Adding Infergen to our growing portfolio is very exciting," said Donald J. Kerrish, RPh, Three River's president and chief executive officer. "This purchase is only a beginning for Three Rivers' continuous strategy to increase its product offerings through product acquisition and internal product development of pharmaceutical therapies."

Infergen, or consensus interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease and is dosed three times per week.

Important Safety Information

Physicians and patients can obtain additional prescribing information regarding Infergen, including the product's safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting www.infergen.com.

About Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania and focuses on specialized therapies including hepatitis C therapies. Three Rivers is the first drug company to focus on the needs of the emerging specialty market. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community.

The company's mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on specialized therapies because of our extensive knowledge and experience in this area. More information about the company can be found at www.3riverspharma.com.

Suggested Articles

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.